Clinic Roundup

• Addex Therapeutics SA, of Geneva, reported top-line data showing that a Phase IIa trial testing dipraglurant, a small-molecule allosteric modulator, in Parkinson's disease patients suffering from debilitating levodopa-induced dyskinesia (LID) met its primary endpoint, with the drug exhibiting a good safety and tolerability profile.